V. Valov

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria

G. Angelova, M. Kamusheva, G. Petrova, 2020, PloS one.

Comparative Analysis of the Cost of Insulin Treated Patients in Bulgaria

G. Petrova, M. Czech, M. Manova, 2013 .

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects

G. Angelova, M. Kamusheva, G. Petrova, 2019, Front. Pharmacol..

Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA

G. Angelova, M. Kamusheva, G. Petrova, 2018, International Journal of Diabetes in Developing Countries.

Regional differences in diabetic patients' pharmacotherapy in Bulgaria.

G. Petrova, M. Czech, M. Manova, 2014, European review for medical and pharmacological sciences.

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

M. Manova, A. Savova, V. Valov, 2019, BMC endocrine disorders.

Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

G. Petrova, M. Czech, V. Petkova, 2015 .

Improved quality of diabetes control reduces complication costs in Bulgaria

G. Angelova, M. Kamusheva, G. Petrova, 2019, Biotechnology & Biotechnological Equipment.

Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria

G. Petrova, M. Czech, A. Savova, 2012 .